Dabarun jiyya don myelofibrosis na farko (PMF) sun dogara ne akan ƙaddamar da haɗari.Saboda nau'o'in bayyanar cututtuka da al'amurran da za a magance a cikin marasa lafiya na PMF, dabarun jiyya suna buƙatar la'akari da cutar mai haƙuri da bukatun asibiti.Jiyya na farko tare da ruxolitinib (Jakavi / Jakafi) a cikin marasa lafiya tare da babban ƙwayar cuta ya nuna raguwa mai mahimmanci kuma ya kasance mai zaman kanta daga matsayin maye gurbin direba.Mafi girman girman raguwar ɓarna yana nuna mafi kyawun tsinkaya.A cikin marasa lafiya marasa lafiya ba tare da wata cuta mai mahimmanci na asibiti ba, ana iya lura da su ko shigar da su cikin gwaji na asibiti, tare da sake dubawa kowane watanni 3-6.Ruxolitinib(Jakavi/Jakafi) maganin miyagun ƙwayoyi za a iya farawa a cikin ƙananan-ko matsakaici-haɗari-1 marasa lafiya waɗanda ke tare da splenomegaly da / ko cututtuka na asibiti, bisa ga jagororin jiyya na NCCN.
Don matsakaitan-haɗari-2 ko marasa lafiya masu haɗari, an fi son allogeneic HSCT.Idan ba a samu dasawa ba, ana ba da shawarar ruxolitinib (Jakavi/Jakafi) azaman zaɓin jiyya na layin farko ko don shigar da gwaji na asibiti.Ruxolitinib (Jakavi/Jakafi) shine kawai maganin da aka yarda da shi a halin yanzu a duk duniya wanda ke yin niyya ga hanyar JAK/STAT mai wuce gona da iri, cututtukan MF.Nazarin guda biyu da aka buga a cikin New England Journal da Journal of Leukemia & Lymphoma sun nuna cewa ruxolitinib (Jakavi / Jakafi) na iya rage yawan cutar da inganta rayuwar marasa lafiya tare da PMF.A cikin tsaka-tsaki-2 da kuma marasa lafiya na MF masu haɗari, ruxolitinib (Jakavi / Jakafi) ya iya rage ƙwayar ƙwayar cuta, inganta cututtuka, inganta rayuwa, da inganta yanayin ƙwayar kasusuwa, saduwa da manufofin farko na kula da cututtuka.
PMF yana da yuwuwar aukuwa na shekara-shekara na 0.5-1.5/100,000 kuma yana da mafi munin hasashen duk MPNs.PMF yana da alaƙa da myelofibrosis da extramedullary hematopoiesis.A cikin PMF, fibroblasts na kasusuwa na kasusuwa ba a samo su daga ƙananan clones ba.Kusan kashi ɗaya bisa uku na marasa lafiya tare da PMF ba su da alamun bayyanar cututtuka a lokacin ganewar asali.Ƙorafe-ƙorafe sun haɗa da gagarumin gajiya, anemia, rashin jin daɗi na ciki, gudawa saboda satiety da wuri ko splenomegaly, zubar jini, asarar nauyi, da edema na gefe.Ruxolitinib(Jakavi/Jakafi) an amince da shi a watan Agusta 2012 don kula da matsakaici ko babban haɗari myelofibrosis, ciki har da myelofibrosis na farko.A halin yanzu ana samun maganin a cikin ƙasashe sama da 50 a duniya.